book contributions

Patent number: 9050282

Abstract: The present invention provides compositions and methods for eliciting protective immunity in animals against Leptospira interrogans (LI) serovar copenhageni. The invention is based, in part, on the unexpected cross-protection against heterologous LI serovar, which resulted when canines were administered an effective amount of RECOMBITEK® 4 Lepto, then subsequently challenged with virulent L. copenhageni (Fiocruz L1-130).

Publication number: 20140023678

Abstract: The present invention provides compositions and methods for eliciting protective immunity in animals against Leptospira Interrogans (LI) serovar copenhageni. The invention is based, in part, on the unexpected cross-protection against heterologous LI serovar, which resulted when canines were administered an effective amount of RECOMBITEK® 4 Lepto, then subsequently challenged with virulent L. copenhageni (Fiocruz L1-130).

Patent number: 7582302

Abstract: The invention provides a novel method of vaccination of an animal of the felidae family against feline leukemia. The FeLV recombinant vaccine based on viral vector with the aid of a liquid jet needle-free injector can result in distribution of the vaccine essentially in the dermis and the hypodermis of the animal.

History of rabies in Colombia the time for an intentional One Health approach is now.

Becerra Natalia C, Pardo MC, Jimenez Luis CV, Polo Luis J

XXXIV RITA Conference - Bogota, Colombia, Feb 2024

History of rabies in Colombia the time for an intentional One Health approach is now

Pardo MC, Jimenez Luis CV, Polo Luis J

XXXIV RITA Conference - Bogota, Colombia, Oct 2023

A new chapter for an integrated rabies research, surveillance, prevention and control in Colombia: the commitment of the Rabies In The Americas (RITA) conference 2023

Natalia Cediel, Paula Bermudez, Nathalia Mendez, Leonardo Roa, Wilmer E. Villamil-Gomez, Alfonso J. Rodriguez-Morales

XXXIV RITA Conference - Bogota, Colombia, Oct 2023

History of rabies vaccination in Colombia: a current need for a One Health approach.

Poulet H, Minke JM, Pardo MC, Juillard V, Nordgren B, Audonnet 

JC. VACCINE 2007 Jul 26;25(30):5606-12 

Fifteen-month duration of immunity for the serovar Grippotyphosa fraction of a tetravalent canine leptospirosis vaccine. 

Grosenbaugh DA, Pardo MC, 

Veterinary Record  2018 Feb 19

Occurrence of canine parvovirus type 2c in the United States. 

Hong C, Decaro N, Desario C, Tanner P, Pardo MC, Sanchez S, Buonavoglia C, Saliki J. 

J Vet Diagn Invest 2007 Sep;19(5):535-539.

Development and Registration of recombinant veterinary vaccines. The example of the Canarypox vector platform.  

Poulet H, Minke JM, Pardo MC, Juillard V, Nordgren B, Audonnet 

JC. VACCINE 2007 Jul 26;25(30):5606-12 

Efficacy of a canarypox-vectored recombinant vaccine expressing the hemagglutinin gene of equine influenza H3N8 virus in the protection of ponies from viral challenge. 

Minke JM, Toulemonde CE, Coupier H, Guigal PM, Dinic S, Sindle T, Jessett D, Bublot M, Pardo MC, Audonnet JC. 

Am. J. Vet. Res. 2007 Feb;68(2):213-9

Immunization of Puppies in the presence of Maternally Derived Antibodies Against Canine Distemper Virus. 

MC Pardo, P Tanner, J Bauman, K Silver, L Fischer. 

Journal of Comparative Pathology. 2007 July. Volume 137 Supplement 1; S72-S75

Protection from challenge following administration of a canarypox virus-vectored recombinant feline leukemia virus vaccine in cats previously vaccinated with a killed virus vaccine. 

Grosenbaugh DA, Leard T, Pardo MC. J 

Am Vet Med Assoc. 2006 Mar 1;228(5):726-7.

Comparison of the safety and efficacy of a recombinant feline leukemia virus (FeLV) vaccine delivered transdermally and an inactivated FeLV vaccine delivered subcutaneously. 

Grosenbaugh DA, Leard T, Pardo MC. 

Vet Ther. 2004;5(4):258-62.

Vaccination of puppies born to immune dams with a canine adenovirus-based vaccine protects against a canine distemper virus challenge.

Fischer L, Tronel JP, Pardo-David C, Tanner P, Colombet G, Minke J, Audonnet JC

VACCINE, Volume 4;20(29-30):3485-3497. October 2002 

Comparison of the safety of a new modified live virus vaccine against canine coronavirus.

M. Camila Pardo, DVM, MS.  Marc Mackowiak, DVM

Canine Practice 2000; 25(1): 16-19.

Efficacy of a New Canine origin, MLV vaccine against Canine Coronavirus.

M. Camila Pardo, DVM, MS.  Marc Mackowiak, DVM

Canine Practice, Volume 24. No1, February 1999

Protection of dogs against Canine Distemper (CDV) by vaccination with a canarypox virus recombinant expressing CDV F and HA glycoproteins.

M. Camila Pardo, John E. Bauman, and Marc Mackowiak. 

American Journal of Veterinary Research, Vol 58, No 8. 833-836. August 1997. 

 Canarypox Vectored Recombinant Vaccine without Adjuvant.

 LCIGP (4-way) inactivated non adjuvanted canine leptospira bacterin with unique 15.5-month duration of immunity against L. Grippotyphosa and Prevention claim 

 Canarypox Vectored Recombinant Vaccine without adjuvant - Transdermal route 

 Canine Distemper, Canarypox vectored Monovalent Vaccine for use in Ferrets .

Vectorized Recombinant Canine Distemper, Canarypox vectored Vaccine without adjuvant for dogs and ferrets. Various Presentations C3, C4, C6 and C8 for Dogs since 1997. (Monovalent for Ferrets in 2001 and Monovalent for Dogs in 2013). First genetically engineered vaccine licensed for pets in the world.

 monovalent and several product combination presentations